Posted by Michael Wonder on 24 Oct 2020
FDA approves FoundationOneCDx as companion diagnostic for Vitrakvi (larotrectinib) to aid in identifying NTRK fusion positive patients
23 October 2020 - Detection of genomic alterations that drive the growth and spread of the tumour can guide treatment decisions for cancer therapies, including available biomarker driven treatments.
Bayer announced that the U.S. FDA approved FoundationOneCDx for use as the first companion diagnostic to help identify neurotrophic receptor tyrosine kinase gene fusion positive patients for whom treatment with Vitrakvi (larotrectinib) may be appropriate.
FoundationOne CDx is an FDA approved comprehensive genomic profiling test for all solid tumours that incorporates multiple companion diagnostic indications, which will advance broader biomarker testing access for the cancer community.
